Malabre Richard C
SVP, Chief Accounting Officer
Malabre Richard C has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 4, 2026.
On the most recent filing, Malabre Richard C is listed as SVP, Chief Accounting Officer at Akebia Therapeutics, Inc. Inside the rolling window, Malabre Richard C reported no open-market purchases and 1 open-market sale totaling $69K in AKBA.
Companies traded
Other insiders at AKBA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$69K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Malabre Richard C made?
Malabre Richard C has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Malabre Richard C trade?
Malabre Richard C has filed SEC Form 4 disclosures for 1 company, including AKBA.
When was Malabre Richard C's most recent SEC Form 4 filing?
Malabre Richard C's most recent SEC Form 4 filing on Tracefour is dated Feb 4, 2026.
What is Malabre Richard C's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Malabre Richard C is listed as SVP, Chief Accounting Officer.
What is Malabre Richard C's total buy and sell value in the current window?
Inside the rolling retention window, Malabre Richard C bought $0 and sold $69K based on SEC Form 4 filings.
What was Malabre Richard C's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 49,524 AKBA shares on 2026-02-02, worth $69K, per SEC Form 4 filings.